CELG
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FCELG.O%2Fkey-developments%2Farticle%2F2855947&ei=knKaUrDjLa210AHc1AE&usg=AFQjCNGUviQ1t0JWwq0BxpaqkFxxyNX7Mg
Celgene Corp's Celgene International Sarl Announces Improvements in Oral Ulcers in Patients with Behçet’s Disease In Phase II Trial
Monday, 28 Oct 2013 07:32am EDT
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation announced the phase II trial (BCT-001) results of apremilast, the Company's first-in-class, oral, targeted inhibitor of phosphodiesterase 4 (PDE4), in patients with Behçet's disease. The findings were presented at the 2013 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting in San Diego. These data, which were also presented at the European League Against Rheumatism (EULAR) annual meeting this year in June, showed that significantly more patients on apremilast achieved a complete response (were free from active oral ulcers) at week 12 compared with those on placebo (apremilast, 71%; placebo, 29%; p
